Teva Pharma (TEVA) – Major News
-
Teva Pharma (TEVA) Tops Q4 EPS by 23c, offers outlook
-
Teva Pharma (TEVA) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY23 Guidance
-
Teva Pharma (TEVA) Tops Q2 EPS by 3c, Offers Guidance
-
Teva Pharma (TEVA) Misses Q1 EPS by 15c, Revenue Beats, Offers Guidance
-
Teva Pharma (TEVA) Reports In-Line Q4 EPS, Offers Guidance
-
Teva Pharma (TEVA) Misses Q3 EPS by 3c; Lowers Revenue Outlook on FX
-
Teva Pharma (TEVA) Tops Q2 EPS by 12c, Offers Guidance
-
Teva Pharma (TEVA) Reports In-Line Q1 EPS; Narrows Guidance
-
Teva Pharma (TEVA) Tops Q4 EPS by 4c
-
Teva Pharma (TEVA) Misses Q3 EPS by 6c
-
Teva Pharma (TEVA) Reports In-Line Q2 EPS; Lowers Revenue Outlook
-
Teva Pharma (TEVA) Tops Q1 EPS by 4c, Revenues Miss; Offers FY21 EPS/Revenue Guidance
-
Teva Pharma (TEVA) Tops Q4 EPS by 5c, Revenues Beat; Offers FY21 EPS/Revenue Guidance
-
Teva Pharma (TEVA) Reports In-Line Q3 EPS, Offer FY Guidance
-
Teva Pharma (TEVA) Tops Q2 EPS by 2c, Affirms Outlook
-
Teva Pharma (TEVA) Tops Q1 EPS by 17c, Revenues Beat; Offers FY20 EPS/Revenue Guidance
-
UPDATE: Teva Pharma (TEVA) Tops Q4 EPS by 1c, Offers FY20 Guidance
-
Teva Pharma (TEVA) Misses Q3 EPS by 1c, Updates FY Guidance
-
Teva Pharma (TEVA) Tops Q2 EPS by 3c, Reaffirms Guidance
-
Teva Pharma (TEVA) Tops Q1 EPS by 2c, Revenues Miss
-
Teva Pharma (TEVA) Misses Q4 EPS by 1c, FY Guidance Misses
-
Teva Pharma (TEVA) Tops Q3 EPS by 11c; Raises Outlook
-
Teva Pharma (TEVA) Announces FDA Approval for AJOVYTM Injection to Treat Migraine
-
FDA Approves Teva Pharma (TEVA) Generic Epipen
-
Teva Pharma (TEVA) Tops Q2 EPS by 14c; Raises Outlook
-
Teva Pharma (TEVA) Tops Q1 EPS by 28c, Raises FY Guidance
-
The Oracle of Omaha Goes Value Shopping in the Value Pharmaceutical Bin with Teva (TEVA)
-
Teva Pharma (TEVA) Tops Q4 EPS by 17c, FY18 Guidance Falls Short of Views
-
Teva Pharma (TEVA) Announces Restructuring Plan; To Cut 14,000 Jobs and Suspend Dividend
-
UPDATE: Teva Pharma (TEVA) Misses Q3 EPS by 4c, Q4 Guidance Comes in Light
-
Teva Pharma (TEVA) Announces Kare Schultz as President & CEO
-
Teva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts Dividend
-
AstraZeneca (AZN) CEO Departure Could Be Announced as Soon as Tonight - Source
-
Teva Pharma (TEVA) Reports In-Line Q1 EPS, Reaffirms Outlook
-
Teva Pharma (TEVA) Tops Q4 EPS by 2c; Reaffirms
-
Teva Pharma (TEVA) CEO Erez Vigodman to Step Down; Dr. Yitzhak Peterburg Named as Interim CEO
-
Teva Pharma (TEVA) Sees 2017 EPS of $4.90-$5.30, Versus Consensus of $5.41
-
Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook
-
Teva Pharma (TEVA) Tops Q2 EPS by 5c; Guides In-Line
-
Teva Pharma (TEVA) Raises Q2 Outlook
-
Teva Pharma (TEVA) to Suspends Sales of ZECUITY in the U.S.
-
Teva Pharma (TEVA) Tops Q1 EPS by 3c
-
Teva Pharma (TEVA) Misses Q4 EPS by 1c
-
Teva Pharma (TEVA) Tops Q3 EPS by 7c; Boosts FY15 EPS Outlook
-
Teva Pharma (TEVA) to Acquire Rimsa in $2.3B Deal
-
Teva Pharma (TEVA) Tops Q2 EPS by 12c; Boosts FY15 EPS Outlook
-
Teva Pharma (TEVA) to Acquire Allergan Genetics (AGN) in $40.5B Cash and Stock Deal
-
Teva Pharma (TEVA) Nears Deal to Acquire Allergan's (AGN) Generic-Drug Business
-
Teva Pharma (TEVA) Tops Q1 EPS by 11c
-
Mylan (MYL) Rejects Unsolicited Teva (TEVA) Proposal
Back to TEVA Stock Lookup